LB Pharmaceuticals (NASDAQ:LBRX) Stock Price Down 5.4% Following Analyst Downgrade

Key Points

• LB Pharmaceuticals shares fell 5.4% to approximately $35 after Roth Capital downgraded the stock from Buy to Neutral and cut its price target from $37 to $35.
• Analyst sentiment remains broadly positive, with a consensus rating of Moderate Buy and an average price target of $51.44, despite recent downgrades and mixed individual ratings.
• The company reported a quarterly loss of $1.71 per share, missing the $0.84 consensus estimate, while developing LB-102, an oral schizophrenia treatment candidate.

Shares of LB Pharmaceuticals Inc (NASDAQ:LBRX - Get Free Report) dropped 5.4% during mid-day trading on Monday after Roth Capital downgraded the stock from a buy rating to a neutral rating. Roth Capital now has a $35.00 price target on the stock, down from their previous price target of $37.00. LB Pharmaceuticals traded as low as $35.08 and last traded at $35.0050. 311,784 shares were traded during mid-day trading, an increase of 12% from the average daily volume of 277,335 shares. The stock had previously closed at $36.99.

A number of other research analysts have also recently commented on LBRX. Wolfe Research assumed coverage on LB Pharmaceuticals in a research report on Tuesday, July 7th. They set an "outperform" rating and a $45.00 price target on the stock. Wall Street Zen lowered LB Pharmaceuticals from a "sell" rating to a "strong sell" rating in a report on Saturday. Piper Sandler restated an "overweight" rating and issued a $78.00 price objective on shares of LB Pharmaceuticals in a research note on Monday, August 3rd. Stifel Nicolaus set a $53.00 target price on shares of LB Pharmaceuticals in a research report on Thursday, August 13th. Finally, Weiss Ratings downgraded shares of LB Pharmaceuticals from a "sell (d+)" rating to a "sell (d)" rating in a research note on Tuesday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $51.44.

Institutional Trading of LB Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Spruce Street Capital LP boosted its stake in LB Pharmaceuticals by 36.9% in the 1st quarter. Spruce Street Capital LP now owns 1,376,159 shares of the company's stock worth $33,645,000 after purchasing an additional 370,566 shares during the period. Eversept Partners LP purchased a new stake in shares of LB Pharmaceuticals in the first quarter worth about $2,471,000. Wellington Management Group LLP boosted its position in shares of LB Pharmaceuticals by 11.9% in the second quarter. Wellington Management Group LLP now owns 58,891 shares of the company's stock valued at $1,911,000 after acquiring an additional 6,251 shares during the period. Bank of New York Mellon Corp purchased a new position in LB Pharmaceuticals during the second quarter valued at approximately $1,784,000. Finally, Janus Henderson Group PLC purchased a new position in LB Pharmaceuticals during the first quarter valued at approximately $1,613,000.

LB Pharmaceuticals Trading Down 5.4%

The firm has a market cap of $1.13 billion and a P/E ratio of -10.17. The stock's fifty day moving average is $44.16 and its two-hundred day moving average is $34.56.

LB Pharmaceuticals (NASDAQ:LBRX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.87). On average, analysts forecast that LB Pharmaceuticals Inc will post -5.78 EPS for the current year.

LB Pharmaceuticals Company Profile

LB Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system and neuropsychiatric disorders. The company's lead product candidate is LB-102, an oral prodrug of amisulpride, an established antipsychotic medicine that is approved in certain countries outside the United States but is not currently approved in the U.S.

LB-102 is being developed for the treatment of schizophrenia, with the company seeking to evaluate its potential to address the needs of patients and healthcare providers in the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.